Trial Profile
Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Apr 2024
Price :
$35
*
At a glance
- Drugs EIK 1001 (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Cholangiocarcinoma; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Birdie Biopharmaceuticals
- 05 Apr 2024 According to a Florida Cancer Specialists & Research Institute Clinical Research media release, data from this trial will be presented at the American Association for Cancer Research 2024 Annual Meeting in San Diego.
- 30 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Mar 2024.
- 15 Jun 2023 Planned End Date changed from 1 Dec 2022 to 1 Mar 2024.